Verona Pharma (VRNA) on Tuesday said it expects Q4 net product sales of $36 million on the back of the commercial launch of Ohtuvayre, a treatment for chronic obstructive pulmonary disease, a lung condition.
Full-year 2024 net product sales are expected to be $42 million, the company said.
Meanwhile, the company said it expected to report $400 million in cash and cash equivalents as of Dec. 31, 2024.
Price: 48.95, Change: +4.14, Percent Change: +9.24
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments